TP53 and neoplasm: To assess whether DNA-based anti-p53-R175H mAb or BsAb could target the mutant antigen presented on tumor cells in vivo, we administered pR175H-mAb, pR175H-BsAb, or the control plasmid intramuscularly by electroporation in MC38-p53-R175H or CT26-p53-R172H models.